BGB-3245+Panitumumab in Advanced/Metastatic RAS mutant CRC & Pancreatic Ductal Cancers (MapKure) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if the combination of an experimental drug called BGB-3245 (the study drug) and panitumumab is a safe and effective option for patients who have colorectal or pancreatic cancer with an RAS mutation.
Advanced or Metastatic RAS Mutant Colorectal Cancer and Pancreatic Ductal Cancers
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with advanced or metastatic RAS mutant colorectal cancer; OR
- Are diagnosed with RAS mutant pancreatic ductal cancer
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
What is Involved?
If you choose to join this study, you will:
- Take the study drug in combination with panitumumab
- Have a tumor biopsy done, if necessary
- Have blood draws
- Have imaging scans (CT or MRI)
Study Details
